ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.263,01
1,30%
S&P 500
5.725,55
0,12%
US Dollar vs BRL
5,4593
-1,41%
Bitcoin
63.641,45
0,50%
Brent Oil
74,475
1,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Gilead Sciences Inc (GILD)

  7. Gilead Sciences Inc (GILD) Notícias

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GILD
DataHoraFonteTítuloCódigoCompanhia
13/09/202420:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
12/09/202417:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GILDGilead Sciences Inc
12/09/202409:30Business WireGilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 TrialNASDAQ:GILDGilead Sciences Inc
10/09/202409:00Business WireGilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel TherapiesNASDAQ:GILDGilead Sciences Inc
05/09/202409:00Business WireGilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung CancerNASDAQ:GILDGilead Sciences Inc
21/08/202417:05Business WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
14/08/202414:59Business WireGilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDANASDAQ:GILDGilead Sciences Inc
08/08/202418:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
08/08/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
08/08/202417:02Business WireGilead Sciences Announces Second Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
08/08/202406:55IH Market NewsU.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices StallNASDAQ:GILDGilead Sciences Inc
25/07/202417:05Business WireGilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:GILDGilead Sciences Inc
25/07/202410:15Business WireGilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and PipelineNASDAQ:GILDGilead Sciences Inc
24/07/202405:30Business WireFull Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024NASDAQ:GILDGilead Sciences Inc
22/07/202405:00Business WireGilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central AsiaNASDAQ:GILDGilead Sciences Inc
17/07/202409:50Business WireChief Medical Officer Merdad Parsey to Leave Gilead Early 2025NASDAQ:GILDGilead Sciences Inc
16/07/202409:30Business WireGilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024NASDAQ:GILDGilead Sciences Inc
26/06/202411:45PR Newswire (Canada)EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIHNASDAQ:GILDGilead Sciences Inc
21/06/202409:00IH Market NewsHoneywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues GainsNASDAQ:GILDGilead Sciences Inc
20/06/202409:51Business WireGilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV PreventionNASDAQ:GILDGilead Sciences Inc
17/06/202407:49IH Market NewsGoldman Sachs Raises S&P 500 Forecast for 2024; Disney Secures Deadpool & Wolverine in Chinese Cinemas, and MoreNASDAQ:GILDGilead Sciences Inc
14/06/202404:00Business WireNew Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentNASDAQ:GILDGilead Sciences Inc
06/06/202405:30Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNANASDAQ:GILDGilead Sciences Inc
05/06/202403:00Business WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
03/06/202411:00Business WireKite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNASDAQ:GILDGilead Sciences Inc
03/06/202410:00Business WireEncouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System LymphomaNASDAQ:GILDGilead Sciences Inc
02/06/202409:00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
01/06/202409:00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
31/05/202409:07Business WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024NASDAQ:GILDGilead Sciences Inc
30/05/202417:45Business WireGilead Provides Update on Phase 3 TROPiCS-04 StudyNASDAQ:GILDGilead Sciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GILD

Seu Histórico Recente

NASDAQ
MDBH
MDB Capital
NASDAQ
FICVU
Frontier Investment
CRTO
PLAUSD
PlayDapp Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados